Arca
Skip to content

Herpes zoster

Drug research and approvals for herpes zoster: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 53 studies of herpes zoster are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 53
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 53 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Sep 11, 2023A phase I/ii, observer-blind, randomised, placebo-controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an…HERPES SIMPLEX VIRUS (HSV)-TARGETED IMMUNOTHERAPY (GSK3943104A)GSKOngoing
May 24, 2018"safety and immunogenicity of non-live, recombinant subunit herpes zoster vaccine in vzv-seronegative solid organ transplant recipients."SHINGRIXUNIVERSITY HEALTH NETWORKPending
Mar 1, 2018Immunogenicity and safety study of gsk biologicals' herpes zoster vaccine gsk1437173a when co-administered with prevenar13 in adults aged 50 years and olderSHINGRIXGSKClosed
Apr 1, 2016A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (zoe-ltfu) of studies 110390 and 113077 (zoster-005/022) to assess the…HERPES ZOSTER SUBUNIT VACCINE (HZ/SU) (GSK1437173A)GSKOngoing
Mar 11, 2016A phase IIIb, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of gsk biologicals' herpes zoster subunit…HERPES ZOSTER SUBUNIT VACCINE (GSK1437173A)GSKOngoing
Nov 27, 2014A phase III, randomized, double blind multicenter study, to evaluate consistency, immunogenicity, safety and reactogenicity of 3 lots of gsk biologicals'…HERPES ZOSTER (HZ) VACCINEGSKOngoing
Dec 10, 2013A phase III, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of gsk biologicals' herpes zoster vaccine gsk1437173a…HERPES ZOSTER (HZ) VACCINE (GSK1437173A)GSKPending
Sep 6, 2013A phase III, randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety of gsk biological's herpes zoster vaccine gsk1437173a…HERPES ZOSTER (HZ) VACCINEGSKOngoing
Apr 24, 2013"a phase III, randomised, observer-blind, placebo controlled, multicentre clinical study to assess the immunogenicity and safety of gask biologicals hz/su…HERPES ZOSTER (HZ) VACCINEGSKOngoing
Apr 11, 2013"a phase III, non-randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety gsk biologicals' herpes zoster hz/su candidate…HERPES ZOSTER (HZ) VACCINEGSKClosed

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Nov 9, 1995SorivudineTreatment of herpes zoster (shingles) in immunocompromised patientsBristol-Myers SquibbDesignated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Mar 21, 2018Shingrixherpes zoster vaccine (recombinant, adjuvanted)GlaxoSmithKline Biologicals S.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.